WRAP North America
← catalyst calendarNCT06807099 · readout ≤ 498 d
Sponsored by Merit Medical Systems, Inc. (industry) · MMSI — their whole pipeline →.
Phase
—
Status
Recruiting
Study type
Observational
Enrollment
250estimated
Sites
16
Countries
Canada, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-07-31 | actual | When the study began enrolling |
| Primary completion | Dec 2027 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Jul 2030 | estimated | The whole study's end, after follow-up |
| First posted | 2025-02-04 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-17 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Venous Stenosis
- Venous Occlusion
Intervention
- Device: Merit WRAPSODY® Cell Impermeable Endoprosthesis (WRAPSODY CIE)
Primary outcomes
what the primary-completion date above is the date OFProportion of subjects with Target Lesion Primary Patency (TLPP) (Primary Effectiveness Endpoint)
measured 6 months
Proportion of subjects without any localized or systemic safety events (Primary Safety Endpoint)
measured 30 days
Permalink · MMSI's whole pipeline · Catalyst calendar · Every registered study · What changed